Ashley Hall Snyder, PharmD, MPH

** ********* **

Petaluma, CA 94954

970-***-****

ac5iki@r.postjobfree.com

PROFESSIONAL EXPERIENCE

Industry experience,

Research Scientific Director, Infectious Diseases, 2013 – present

Merck Research Labs, Merck & Co, Inc (formerly Cubist Pharmaceuticals), Jan 2015 – present

Upper Gwynedd, PA

Clinical Scientific Director, Cubist Pharmaceuticals (formerly Optimer Pharmaceuticals), Jan 2014 – Dec 2014

Medical Education and Research Liaison, Optimer Pharmaceuticals, Apr 2013 – Dec 2013

Manager: Gigi Ross, PharmD, MBA

One of 5 employees remaining from original company (Optimer). Responsible for business continuity and integration support; integration lead to ensure transition of legacy Optimer programs

Work Force long-range strategic planning: worked with key leadership to outline long-range work force plan, notably expanding from 6 to 9 products, expanding into CMV therapeutic area and vaccine support

Surveillance lead

oEducation/training of research scientific director team surrounding surveillance programs (STAR, PACTS, IHMA)

oCreated interface between key microbiologists and surveillance sites initiative

oCross-functional collaboration between highly matrix environment (late stage and early stage clinical microbiology, product development team, publications, commercial, marketing, strategy, and CRO)

oRepresent team with CRO/external vendor, ensure appropriate lexicon usage, drive publication topic to meet needs of company and external scientific leaders

Expand territory and form relationships, increasing scientific leaders by 500% over 4 years (from 20 to 115)

Support 9 products in 5 therapeutic areas (spanning gram-positive, gram-negative, C. difficile, CMV, and antifungals) 25 clinical trials, and manage 115 scientific leader relationships with 20 international thought leader relationships

Liaison for internal access to funding, navigating through multiple funding mechanisms within Merck (Merck investigator sponsored program [MISP] studies for C. difficile, gram-positive, gram-negative, antifungal, antimicrobial stewardship, as well as outcomes-related funding [CORE]); 82% territory funding rate (average <20%)

Leadership at scientific congresses, planning congress coverage, competitive intelligence efforts and assignments, data interpretation and presentation to senior leadership, build executive level final reports, coordinating research discussions between key scientific leaders and Merck leadership

Business Development and Licensing (special assignment), March 2017 – June 2017

West Coast Innovation Hub, Merck & Co, Inc

San Francisco, CA

Overseeing Manager: Alex Szidon, Assistant Vice President, BD&L

Source and identify potential licensing opportunities from West Coast companies

Areas of current focus- infectious disease and vaccines

Aid in due diligence efforts across research, clinical, development, intellectual property and finance teams

Aid deal structure, final negotiations

Develop decks for Merck Senior Management, focus on research plan, competitive landscape evaluation and timelines

Evaluation of 8 anti-infective and/or vaccine opportunities (high-level technical diligence and evaluation of strategic fit)

Assist deal team with multi-million dollar equity deal closure

Professional experience,

Director, Clinical Research, 2012 – 2013

Henry Ford Hospital, Division of Infectious Diseases

Detroit, MI

Supervisor: Marcus Zervos, MD

Oversee clinical research conducted for the division of Infectious Diseases

Serve as principal investigator for clinical trials, including an NIH-funded study

Lead grant writing

Lead international research program startup, oversight and personnel management

Staff Pharmacist, 2010-2013

Quality Pharmacy Management (qPM),

acquired by PipelineRx

Lakewood, CO

Supervisor: Kevin Jones, RPh, MBA

After hours clinical support

Remote order entry for small community hospitals

Utilize multiple EMR systems

Honorary Clinical Instructor, 2009 – present

University of Colorado Denver School of Pharmacy Department of Clinical Pharmacy, Jul 2009 – present

University of Illinois at Chicago College of Pharmacy Department of Pharmacy Practice,

Jul 2009 – Jul 2010

PUBLICATIONS

Hall Snyder AD, Werth BJ, Nonejuie P, McRoberts JP, Pogliano J, Sakoulas G, Yim J, Singh N, Rybak MJ. Fosfomycin enhances the activity of daptomycin against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic model. (Accepted Antimicrob Agents and Chemother).

Faris J, Mynatt RP, Hall Snyder AD, Rybak MJ. Treatment of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia with ceftaroline fosamil in a patient with inhalational thermal injury. Infect Dis Ther 2015;4(4):519-28.

Hall Snyder AD, Vidaillac C, Rose WE, Rybak MJ. Evaluation of high-dose daptomycin versus vancomycin alone or combined with clarithromycin and rifampin against Staphylococcus aureus and S. epidermidis in a novel in vitro pharmacokinetic/pharmacodynamics (PK/PD) model of bacterial biofilm. Infect Dis Ther 2014;Dec 18 [Epub ahead of print]

Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ. Comment on: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis. J Antimicrob Chemother 2015;70(4):1272-3.

Hall Snyder AD, Werth BW, Sakoulas G, Rybak MJ. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. J Antimicrob Chemother 2014;69(8):2148-54.

Steinke L, Hall Snyder AD, Srivastava R, Rybak MJ, McGrath E. Ceftaroline Fosamil for Methicillin-Resistant Staphlycoccus aureus Pneumonia in a Pediatric Cystic Fibrosis Patient. J Pediatr Pharmacol Ther 2014;19(2):135-40.

Steed ME, Hall AD, Salimnia H, Kaatz G, Kaye K, Rybak MJ. Evaluation of daptomycin non-susceptible Staphylococcus aureus for stability, population profiles, mprF mutations, and daptomycin activity. J Infectious Disease and Therapy 2013;2(2):187-200.

Hall AD, Steed ME, Murray BE, Arias CA, Rybak MJ. Evaluation of standard and high dose daptomycin vs. linezolid against Enterococcus faecium in an in vitro PK/PD model of simulated endocardial vegetations. Antimicrob Agents Chemother 2012;56:5709-14.

Hall AD, LaPlante KL, Rybak MJ (2011). Daptomycin. Antimicrobe Infectious Disease & Antimicrobial Agents. Retrieved from: http://www.antimicrobe.org.

Aistrope DS, Attridge RT, Bickley AR, Browne MR, Hall AD, Miller AE, Sheahan ME, Tilman EM, Trinkley KE. Strategies for Developing Pharmacy Residents as Educators. Pharmacotherapy 2011;31:65e-70e.

Hall A. What place in therapy does oseltamivir 150 mg twice daily have for treatment of H1N1? Frequently asked question. University of Illinois at Chicago Drug Information Group. http://dig.pharm.uic.edu/faq/oseltamivir.aspx. November 2009.

PRESENTATIONS

International

Pharmacodynamics of Antibiotics: Improving Patient Outcomes Through Target Attainment. Invited lecture for International Course on Antimicrobial Resistance. Universidad Peruana Cayetano Heredia-Laboratorio de Enfermedades Entericas y Nutricion Comision organizadora, Lima, Peru; August 2012.

Werth BJ, Hall AD, McRoberts JP, Rybak MJ. Fosfomycin (FOF) Enhances the activity of Daptomycin (DAP) Against Vancomycin-Resistant Enterococcus faecium (VREFm) and faecalis (VREFs) in a One Compartment in vitro Pharmacokinetic/Pharmacodynamic (PK/PD) Model Through Modulation of Cell Surface Charge. Poster presentation at the 23rd European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany; April 2013. Abstract # 1773

Hall AD, Vidaillac C, Rose WE, Rybak MJ. High-dose daptomycin versus vancomycin, alone or combined with clarithromycin or rifampin against methicillin-resistant Staphylococcus epidermidis in an in vitro pharmacokinetic/pharmacodynamic model of bacterial biofilm. Poster presentation at 22nd European Congress of Clinical Microbiology and Infectious Diseases. London, UK; April 2012. Abstract # P-1603.

Hall AD, Steed ME, Murray BE, Arias CA, Rybak MJ. Evaluation of Standard and High Dose Daptomycin Versus Linezolid Against Vancomycin-Resistant Enterococcus faecalis (VREF) in an in vitro Model of Simulated Endocardial Vegetations (SEV). Poster presentation at 22nd European Congress of Clinical Microbiology and Infectious Diseases. London, UK; April 2012. Abstract # P-1604.

National

Hall AD, Ginsburg K, Samuel PS, Kaye KS. Michigan Hospital Antibiogram Survey: Prevalence, Utilization and Health Care Provider Perceptions. Poster presentation at IDWeek. San Francisco, CA; October 2013. Abstract # 1092.

Hall AD, Ginsberg K, Samuel PS, Kaye KS. Identifying Differences in Michigan Hospital Antibiogram Prevalence, Utilization and Perception of Antibiotic Resistance by Geographical Location and Hospital Size. Poster presentation at Michigan State Medical Society. Troy, MI; October 2013.

Taramona C, Hall AD, Moreno D, Angulo D, Astocondor L, Horna G, Mori L, Perri M, Garcia C, Zervos M. Epidemiology of Staphylococcus aureus colonization in health workers in Lima, Peru. Poster presentation at IDWeek. San Francisco, CA; October 2013. Abstract #371.

Arshad S, Hall AD, Marcus MJ. Ceftaroline fosamil (CPT-F) for therapy of methicillin-resistant Staphylococcus aureus bacteremia (MRSAB): Laboratory and clinical outcomes. Poster presentation at 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver, CO; September 2013. Abstract # 1100.

Moreno D, Perri M, Hall A, Angulo D, Taramona C, Mori L, Astocondor L, Horna G, Arshad S, Zervos MJ, Garcia C. Molecular epidemiology of Staphylococcus aureus isolates from Lima, Peru. Poster presentation at 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver, CO; September 2013. Abstract # 962.

Werth BJ, Hall AD, McRoberts JP, Rybak MJ. Fosfomycin (FOF) Enhances the activity of Daptomycin (DAP) Against Vancomycin-Resistant Enterococcus faecium (VREFm) and faecalis (VREFs) in a One Compartment in vitro Pharmacokinetic/Pharmacodynamic (PK/PD) Model Through Modulation of Cell Surface Charge. Poster presentation at the 16th Annual Making a Difference in Infectious Disease (MAD-ID) Meeting. Orlando, FL; May 2013. Poster # 17

Healthcare-associated infections: Targeting zero. Invited lecture for Annual Healthcare Summit Conference. Women in Government. Washington, DC; November 2012.

Arshad S, Moreno D, Shoyinka A, Perri M, Hall AD, Zervos MJ, Alangaden G. Intravenous drug abuse in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: epidemiology, strain characteristics and outcomes. Poster presentation at IDWeek. San Diego, CA; October 2012. Abstract # 36646.

Hall AD, Sakoulas G, Rybak MJ. Evaluation of the novel combination of daptomycin plus ceftriaxone against daptomycin susceptible and daptomycin non-susceptible vancomycin-resistant Enterococcus faecium using an in vitro pharmacokinetic/pharmacodynamic (PK/PD) simulated endocardial vegetation (SEV) model. Poster presentation at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; September 2012. Abstract # A-601.

Hall AD, Werth BJ, McRoberts JP, Rybak MJ. Preliminary evaluation of daptomycin plus fosfomycin against vancomycin-resistant Enterococcus faecium (VREFm) and faecalis (VREFs) using an in vitro pharmacokinetic/pharmacodynamic (PK/PD) bacteremia model. Poster presentation at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; September 2012. Abstract # A-602.

Hall AD, Vidaillac C, Rose WE, Rybak MJ. Evaluation of high-dose daptomycin versus vancomycin, both alone or combined with clarithromycin and rifampin against isolates of Staphylococcus aureus in a novel in vitro PK/PD model of bacterial biofilm. Platform presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 2011.

Hall AD, Steed ME, Murray BE, Arias CA, Rybak MJ. Evaluation of standard and high dose daptomycin vs. linezolid against Enterococcus faecium in an in vitro PK/PD model of simulated endocardial vegetations. Poster presentation at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 2011. Abstract # A2-018.

Hall AD, Didomenico RJ. Short-term mortality after inotropic administration in acute decompensated heart failure: a meta-analysis of randomized controlled trials. Poster presented at 44th Annual ASHP Midyear Clinical Meeting. Las Vegas, NV; December 2009.

Hall AD, Kiser T, Fish DN. Pharmacodynamic evaluation of protein binding of antibiotics in critically ill patients. Poster presented at American College of Clinical Pharmacists 30th Annual Meeting. Anaheim, CA; October 2009.

Regional

Short-Term Mortality After Inotropic Administration in Acute Decompensated Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Presented at 25th Annual Great Lakes Pharmacy Resident Conference. Purdue University, West Lafayette, IN; April 2010.

Hall AD. APhA-ASP Region VIII Delegate Candidate. American Pharmacists Association Academy of Student Pharmacists (APhA-ASP) Midyear Regional Meeting. Anaheim, CA; October 2006.

Local

Clinical Implications of Carbapenem-Resistant Acinetobacter baumannii. ACPE # 121-***-**-***-L01-P. Resident Seminar Series, accredited continuing education lecture for college faculty. University of Illinois at Chicago College of Pharmacy. Chicago, IL; October 2009.

SSRIs and Suicidality. Invited Pharmacy Technician CE, Fort Range Community College. Westminster, CO; November 2007.

EDUCATION AND TRAINING

July 2010 – May 2013 Wayne State University School of Medicine

Masters of Public Health

Detroit, Michigan

Curriculum Advisor: David Bassett, PhD

Practicum and Project Advisor: Keith Kaye, MD, MPH

July 2010 – July 2012 Anti-Infective Research Laboratory

Eugene Applebaum College of Pharmacy & Health Sciences

Wayne State University

Infectious Diseases Pharmacotherapy Fellowship

Detroit, Michigan

ACCP Approved (November 1992 - May 2015)

Director: Michael Rybak, PharmD, MPH

July 2009 – June 2010 University of Illinois Medical Center at Chicago

PGY-1 Pharmacy Practice Residency

Chicago, Illinois

Director: Frank Paloucek, PharmD, DABAT, FCCP

August 2009 – June 2010 University of Illinois College of Pharmacy

Resident Teaching Certificate Program

Chicago, Illinois

Program Coordinator: Brad Cannon, PharmD

August 2005 – May 2009 University of Colorado Denver School of Pharmacy

Doctorate of Pharmacy, with Honors

Denver, Colorado

August 2002 – May 2005 Texas Tech University

Animal Science

Lubbock, Texas

LICENSURE AND CERTIFICATION

July 2017 – Present Registered Pharmacist, License No. 76834

California State Board of Pharmacy

August 2009 – Present Registered Pharmacist, License No. 18405

Colorado Board of Pharmacy

July 2009 American Heart Association Adult Cardiopulmonary Life Support

September 2006 Pharmacy Based Immunization Delivery Certificate Training Program

American Pharmacists Association

HONORS AND AWARDS

September 2012 ASM Student & Post-Doctoral Fellows Travel Grant

52nd Interscience Conference on Antimicrobial Agents and Chemotherapy

September 2011 ICAAC Infectious Diseases Fellows Grant Program

51st Interscience Conference on Antimicrobial Agents and Chemotherapy

April 2010 Resident Travel Award

American College of Clinical Pharmacy

October 2009 Resident Travel Award

American College of Clinical Pharmacy

May 2008 Kaiser Permanente Kent M. Nelson Clinical Pharmacy Scholarship

University of Colorado at Denver School of Pharmacy

Fall 2007 Deans List

University of Colorado at Denver School of Pharmacy

May 2007 JM Long Scholarship

University of Colorado at Denver School of Pharmacy

May 2006 King Soopers Scholarship

University of Colorado at Denver School of Pharmacy

May 2005 Dean’s Scholar, Texas Tech University

2002 – 2005 Dean’s Silver Scholarship, Texas Tech University

2002 – 2005 Presidential Endowment Scholarship, Texas Tech University

PROFESSIONAL AFFILIATIONS

2014 – 2015 Junior League of Napa Sonoma

2012 – Present Infectious Diseases Society of America (IDSA)

2012 – Present Society for Healthcare Epidemiology of America (SHEA)

2012 – 2016 European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

2010 – Present American Society of Microbiology (ASM)

2010 – Present Society of Infectious Disease Pharmacists (SIDP)

Grants Review Committee (2016-2017)

Political Advocacy Committee (2013-2014)

Programming Committee (2012-2013)

2007 – 2015 American College of Clinical Pharmacy (ACCP)

Resident Advisory Committee Member (2009-2010)

Organizational Affairs Committee Member (2008-2009)

2006 – Present Phi Lambda Sigma (PLS) Leadership Society – Alpha Xi Chapter

2005 – 2013 American Society of Health-System Pharmacists (ASHP)

2005 – 2009 American Pharmacists Association (APhA)

President (2007-2008)

President-elect (2006-2007)

Regional Representative, National Officer Nominating Committee (2008)

Midyear Regional Meeting Exhibitor Committee Chair (Oct 2007)

PROFESSIONAL SERVICE

July 2016 – Present Peer Reviewer, Journal of Clinical Pharmacology

September 2010 – Present Peer Reviewer, Pharmacotherapy

2008 – Present P1 Writing Preceptor, University of Colorado Denver School of Pharmacy

Fall 2007 APhA Flu Shot Clinics, Walgreens; Denver, CO

March 2007 Timmy Foundation Medical Missions Trip; Quito, Ecuador

TRAINING COURSEWORK

October 2016 Harnessing Stress for Success 1 week training course

June 2016 Managing Conflict in a Virtual Environment

May 2016 High Impact Communication Skills

February 2016 Harvard Mentor Manager

SPECIAL SKILLS

Medical Spanish

Contact this candidate